Abstract
Breast cancer is one of the most common types of cancer in women, and is the second leading cause of cancer-related deaths in the United States. Chemoprevention using phytoestrogens (PEs) for breast cancer may be a valid strategy. PEs are phytochemicals with estrogen-like structures and can be classified into four types: isoflavones, lignans, stilbenes and coumestans. They are widely distributed in diet and herbs and have shown anti-cancer activity via mechanisms including estrogen receptor modulation, aromatase inhibition, and anti-angiogenesis. Genistein, daidzein and resveratrol are some of the most studied PE examples. Quality control in product manufacturing and clinical study design is a critical issue in developing them as clinically effective chemopreventive agents for breast cancer.
Keywords: Phytoestrogens, Breast cancer, Chemoprevention, Estrogen receptor modulator, Aromatase inhibitor, Genistein, Daidzein, Glycitein, Equol, Matairesinol, Secoisolariciresinol, Sesamin, Enterolactone, Enterodiol, Resveratrol, Coumestrol
Anti-Cancer Agents in Medicinal Chemistry
Title:Developing Phytoestrogens for Breast Cancer Prevention
Volume: 12 Issue: 10
Author(s): Mandy M. Liu, Ying Huang and Jeffrey Wang
Affiliation:
Keywords: Phytoestrogens, Breast cancer, Chemoprevention, Estrogen receptor modulator, Aromatase inhibitor, Genistein, Daidzein, Glycitein, Equol, Matairesinol, Secoisolariciresinol, Sesamin, Enterolactone, Enterodiol, Resveratrol, Coumestrol
Abstract: Breast cancer is one of the most common types of cancer in women, and is the second leading cause of cancer-related deaths in the United States. Chemoprevention using phytoestrogens (PEs) for breast cancer may be a valid strategy. PEs are phytochemicals with estrogen-like structures and can be classified into four types: isoflavones, lignans, stilbenes and coumestans. They are widely distributed in diet and herbs and have shown anti-cancer activity via mechanisms including estrogen receptor modulation, aromatase inhibition, and anti-angiogenesis. Genistein, daidzein and resveratrol are some of the most studied PE examples. Quality control in product manufacturing and clinical study design is a critical issue in developing them as clinically effective chemopreventive agents for breast cancer.
Export Options
About this article
Cite this article as:
M. Liu Mandy, Huang Ying and Wang Jeffrey, Developing Phytoestrogens for Breast Cancer Prevention, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (10) . https://dx.doi.org/10.2174/187152012803833062
DOI https://dx.doi.org/10.2174/187152012803833062 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting the Role of Astrocytes in the Progression of Alzheimers Disease
Current Signal Transduction Therapy Methods to Access 2-aminobenzimidazoles of Medicinal Importance
Current Organic Chemistry Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
Current Medicinal Chemistry Epidemiology and Pathology of Malignant Mesothelioma
Current Respiratory Medicine Reviews The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance
Current Molecular Medicine Vitamin D and Lung Cancer
Current Respiratory Medicine Reviews Synthesis and Anticancer Properties of Novel Truncated Carbocyclic Nucleoside Analogues
Anti-Cancer Agents in Medicinal Chemistry Cyclooxygenase-2 Inhibition and Gastric Cancer
Current Pharmaceutical Design Recent Advances in Epitope Design for Immunotherapy of Cancer
Recent Patents on Anti-Cancer Drug Discovery Evaluation of Novel Radioiodinated C7-substituted Δ6,7 – estradiol Derivatives for Molecular Recognition of ER-Positive Breast Tumours
Current Radiopharmaceuticals Synthesis and Anti-cancer Activity of 3-substituted Benzoyl-4-substituted Phenyl-1H-pyrrole Derivatives
Anti-Cancer Agents in Medicinal Chemistry Design of New Drug Molecules to be Used in Reversing Multidrug Resistance in Cancer Cells
Current Cancer Drug Targets Probiotics as an Alternative Strategy for Prevention and Treatment of Human Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future
Current Cancer Drug Targets The Role of Diabetes in Molecular Pathogenesis of Cancer
Current Signal Transduction Therapy Establishment of Novel Cells Stably Secreting Various Human IL-18 Recombinant Proteins
Current Pharmaceutical Biotechnology Role of Anti-HER-2 Therapies in the Neo-Adjuvant Setting: Is Complete Pathological Response a Solid Surrogate?
Reviews on Recent Clinical Trials Pharmacokinetics-based Dose Management of 5-Fluorouracil Clinical Research in Advanced Colorectal Cancer Treatment
Mini-Reviews in Medicinal Chemistry Fasting Insulin and Risk of Cancer Related Mortality in Non-diabetic Adults: A Dose-response Meta-analysis of Cohort Studies
Current Diabetes Reviews